ClinicalTrials.gg
CompletedNCT03529110Updated Oct 7, 2026Results posted

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

A Phase 3 interventional study of Trastuzumab deruxtecan (T-DXd) and Ado-trastuzumab emtansine (T-DM1) in Breast Cancer, sponsored by Daiichi Sankyo. Completed at 164 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment

Updated Oct 7, 2026Now CompletedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
524
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Enrollment
7th of 58
524 · median 139
Started
2018
with 5 others
Phase 3
12 of 58
3 open now
Registered
4th of 58
by date
Lead sponsor
9 of 58
Daiichi Sankyo

Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 7th largest by enrollment, is one of 6 that started in 2018, is one of 12 in phase 3, and was the 4th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Metastatic breast cancer
  • DS-8201a
  • DESTINY - Breast 03
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be competent and able to comprehend, sign, and date an Institutional Review Board (IRB) or Ethics Committee (EC) approved ICF before performance of any study-specific procedures or tests.
  2. Adults ≥18 y old. (Please follow local regulatory requirements if the legal age of consent for study participation is >18 y old.)
  3. documented breast cancer that:

    1. is unresectable or .
    2. has confirmed -positive expression as determined according to American Society of Clinical Oncology - College of American Pathologists guidelines evaluated at a central laboratory.23
    3. was previously treated with trastuzumab and taxane in the advanced/ metastatic setting or progressed within 6 mo after or adjuvant treatment involving a regimen including trastuzumab and taxane.
  4. Documented radiologic progression (during or after most recent treatment or within 6 mo after completing adjuvant therapy).
  5. Subjects must be HER2-positive as confirmed by central laboratory assessment of most recent tumor tissue sample available. If archived tissue is not available, a fresh is required.
  6. Presence of at least 1 per modified () version 1.1

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with an anti- ADC (such as T-DM1) in the setting. Prior treatment in the /neoadjuvant setting would be allowed if progression of disease did not occur within 12 mo of end of adjuvant therapy.
  2. Uncontrolled or significant cardiovascular disease, including any of the following:

    1. History of myocardial infarction within 6 mo before randomization;
    2. History of symptomatic congestive heart failure ( Class II to IV);
    3. Troponin levels consistent with myocardial infarction as defined according to the manufacturer within 28 d prior to randomization;
    4. interval (QTc) prolongation to > 470 ms (females) or >450 ms (male) based on average of Screening triplicate 12-lead ;
    5. \< 50% within 28 d prior to randomization
  3. Has a history of (noninfectious) ILD/pneumonitis that required , has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
  4. Spinal cord compression or clinically active central nervous system (CNS) metastases, defined as untreated or symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.

    • Subjects with clinically inactive may be included in the study.
    • Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 wk must have elapsed between the end of whole brain radiotherapy and study enrollment.
  5. Has a history of severe reactions to either the drug substances or inactive ingredients in the drug product.
  6. History of severe hypersensitivity reactions to other mAbs.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
524 participants (actual)

Study arms

  • Experimental
    Trastuzumab deruxtecan (T-DXd)

    Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DXd as a sterile intravenous (IV) solution at a dose of 5.4 mg/kg every 3 weeks (Q3W).

    Drug: Trastuzumab deruxtecan (T-DXd)

  • Active comparator
    Ado-trastuzumab emtansine (T-DM1)

    Participants with HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane who received T-DM1 in accordance with the approved label.

    Drug: Ado-trastuzumab emtansine (T-DM1)

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

    Progression-free survival (PFS) by BICR was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions.

    Time frame: Up to 33 months (data cut-off)

Secondary outcomes

  1. Overall Survival (OS) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

    Overall survival (OS) was defined as the time from the date of first dose of study drug to the date of death due to any cause.

    Time frame: Up to 33 months (data cut-off)

  2. Percentage of Participants With Objective Response Rate (ORR) Based on BICR and Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

    The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by BICR and investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR is reported.

    Time frame: Up to 33 months (data cut-off)

  3. Duration of Response (DoR) Based on BICR and Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

    Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on BICR and investigator assessment is reported.

    Time frame: Up to 33 months (data cut-off)

  4. Progression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

    Progression-free survival (PFS) by investigator assessment was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions.

    Time frame: Up to 33 months (data cut-off)

07

Results

Posted Apr 29, 2022

Participant flow

A total of 524 participants were enrolled and treated at study sites in 14 countries. Primary results reported is from first participant randomized up to data cut-off date of 21 May 2021. The results presented are based on primary analysis up to 33 months. Data collection is still on-going and additional results will be provided after study completion.

Participant flow — Overall Study
MilestoneTrastuzumab Deruxtecan (T-DXd)Ado-trastuzumab Emtansine (T-DM1)
Started261263
Completed13649
Not completed125214
Withdrew: Progressive disease66158
Withdrew: Clinical progression412
Withdrew: Adverse event3517
Withdrew: Withdrawal by subject (from treatment only)1311
Withdrew: Lack of efficacy33
Withdrew: Physician decision28
Withdrew: Miscellaneous25

Outcome measures

PrimaryProgression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

Progression-free survival (PFS) by BICR was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions.

Time frame:
Up to 33 months (data cut-off)
Reported as:
Median · months
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane
monthsTrastuzumab Deruxtecan (T-DXd)Ado-trastuzumab Emtansine (T-DM1)
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and TaxaneNA (18.5 to NA)6.8 (5.6 to 8.2)
SecondaryOverall Survival (OS) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

Overall survival (OS) was defined as the time from the date of first dose of study drug to the date of death due to any cause.

Time frame:
Up to 33 months (data cut-off)
Reported as:
Median · months
Overall Survival (OS) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane
monthsTrastuzumab Deruxtecan (T-DXd)Ado-trastuzumab Emtansine (T-DM1)
Overall Survival (OS) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and TaxaneNA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants With Objective Response Rate (ORR) Based on BICR and Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by BICR and investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR is reported.

Time frame:
Up to 33 months (data cut-off)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response Rate (ORR) Based on BICR and Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane
Percentage of ParticipantsTrastuzumab Deruxtecan (T-DXd)Ado-trastuzumab Emtansine (T-DM1)
BICR79.7 (74.3 to 84.4)34.2 (28.5 to 40.3)
Investigator Assessment77.0 (71.2 to 82.0)36.9 (31.0 to 43.0)
SecondaryDuration of Response (DoR) Based on BICR and Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on BICR and investigator assessment is reported.

Time frame:
Up to 33 months (data cut-off)
Reported as:
Median · months
Duration of Response (DoR) Based on BICR and Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane
monthsTrastuzumab Deruxtecan (T-DXd)Ado-trastuzumab Emtansine (T-DM1)
BICRNA (20.3 to NA)NA (12.6 to NA)
Investigator AssessmentNA (20.8 to NA)NA (14.1 to NA)
SecondaryProgression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

Progression-free survival (PFS) by investigator assessment was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions.

Time frame:
Up to 33 months (data cut-off)
Reported as:
Median · months
Progression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane
monthsTrastuzumab Deruxtecan (T-DXd)Ado-trastuzumab Emtansine (T-DM1)
Progression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane25.1 (22.1 to NA)7.2 (6.8 to 8.3)

Adverse events

Collected over Adverse events (AE) were collected from the date of signing the informed consent form up to 47 days after last dose of the study drug, up 33 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab Deruxtecan (T-DXd)33/257 (12.8%)49/257 (19.1%)256/257 (99.6%)
Ado-trastuzumab Emtansine (T-DM1)53/261 (20.3%)47/261 (18%)249/261 (95.4%)
Most frequent serious events
Showing 10 of 89
Most frequent serious events
EventTrastuzumab Deruxtecan (T-DXd)Ado-trastuzumab Emtansine (T-DM1)
VomitingGastrointestinal disorders5/2572/261
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders5/2570/261
PneumoniaInfections and infestations4/2575/261
PyrexiaGeneral disorders4/2570/261
Disease progressionGeneral disorders3/2571/261
Urinary tract infectionInfections and infestations3/2571/261
AnaemiaBlood and lymphatic system disorders2/2573/261
Platelet count decreasedInvestigations0/2573/261
CellulitisInfections and infestations2/2570/261
Febrile neutropeniaBlood and lymphatic system disorders2/2570/261
Most frequent other events
Showing 10 of 56
Most frequent other events
EventTrastuzumab Deruxtecan (T-DXd)Ado-trastuzumab Emtansine (T-DM1)
NauseaGastrointestinal disorders195/25779/261
VomitingGastrointestinal disorders126/25726/261
Platelet count decreasedInvestigations54/257112/261
Aspartate aminotransferase increasedInvestigations66/257105/261
AlopeciaSkin and subcutaneous tissue disorders95/2578/261
ConstipationGastrointestinal disorders88/25751/261
AnaemiaBlood and lymphatic system disorders83/25743/261
Alanine aminotransferase increasedInvestigations56/25777/261
Decreased appetiteMetabolism and nutrition disorders75/25744/261
Neutrophil count decreasedInvestigations75/25725/261

Baseline characteristics

Baseline characteristics were assessed using the Full Analysis Set.

Age, Categorical
Age, Categorical(Participants)Trastuzumab Deruxtecan (T-DXd)Ado-trastuzumab Emtansine (T-DM1)Total
<=18 years000
Between 18 and 65 years212206418
>=65 years4957106
Age, Continuous
Age, Continuous(years)Trastuzumab Deruxtecan (T-DXd)Ado-trastuzumab Emtansine (T-DM1)Total
Median54.5 ± 11.1154.2 ± 11.8454.4 ± 11.47
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab Deruxtecan (T-DXd)Ado-trastuzumab Emtansine (T-DM1)Total
Female260262522
Male112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trastuzumab Deruxtecan (T-DXd)Ado-trastuzumab Emtansine (T-DM1)Total
American Indian or Alaska Native000
Asian152162314
Native Hawaiian or Other Pacific Islander000
Black or African American10919
White7172143
More than one race202
Unknown or Not Reported262046
08

Study locations

164 sites
  • UCLA Hematology Oncology
    Los Angeles, California 90095, United States
  • Sharp Memorial Hospital
    San Diego, California 92123, United States
  • University of California San Francisco
    San Francisco, California 94115, United States
  • Innovative Clinical Research Institute
    Whittier, California 90603, United States
  • Washington Cancer Institute
    Washington D.C., District of Columbia 20010, United States
  • Florida Cancer Specialists-Broadway
    Fort Myers, Florida 33916, United States
  • Florida Cancer Specialists NORTH
    St. Petersburg, Florida 33705, United States
  • Piedmont Cancer Institute, PC
    Atlanta, Georgia 30318, United States
  • Loyola University Health System
    Maywood, Illinois 60153, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40207, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • North Shore Hematology Oncology Associates, PC
    East Setauket, New York 11733, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45267, United States
  • Seidman Cancer Center
    Cleveland, Ohio 44106, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Dayton Physicians, LLC
    Kettering, Ohio 45409, United States
  • Magee-Womens Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • Tennessee Oncology- St Thomas Location
    Nashville, Tennessee 37205, United States
  • Vanderbilt Breast Center at One Hundred Oaks
    Nashville, Tennessee 37232, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Houston Methodist Hospital / Houston Methodist Cancer Center
    Houston, Texas 77030, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Millennium Oncology
    Houston, Texas 77090, United States
  • The University of Texas Health Science Center at Tyler
    Tyler, Texas 75708, United States
  • MultiCare Health System Institute for Research and Innovation
    Auburn, Washington 98001, United States
  • The Tweed Hospital
    Tweed Heads, New South Wales 2485, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Peninsula and South Eastern Haematology & Oncology Group
    Frankston, Victoria 3199, Australia
  • Peter MacCallum Cancer
    Melbourne, Victoria 3000, Australia
  • St John of God Subiaco Hospital
    Subiaco, Western Australia 6008, Australia
  • Institut Jules-Bordet
    Brussels, 1000, Belgium
  • Universitair Ziekenhuis Brussel
    Brussels, 1090, Belgium
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
  • AZ Sint-Lucas - Campus Sint-Lucas
    Ghent, 9000, Belgium
  • Universitaire Ziekenhuizen Leuven
    Leuven, 3000, Belgium
  • CHU UCL Namur site de Sainte Elisabeth
    Namur, 5000, Belgium
  • NOB - Nucleo de Oncologia da Bahia
    Salvador, Estado de Bahia 40170-110, Brazil
  • Hospital Nossa Senhora da Conceição
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Catarina Pesquisa Clinica
    Itajaí, Santa Catarina 88301-220, Brazil
  • CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
    Santo André, São Paulo 09060-650, Brazil
  • ICESP - Instituto do Cancer do Estado de São Paulo Octavio Frias de Oliveira
    São Paulo, São Paulo 01246-000, Brazil
  • Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda.
    São Paulo, São Paulo 01317-001, Brazil
  • Instituto Americas
    Rio de Janeiro, 22793-080, Brazil
  • A. C. Camargo Cancer Center
    São Paulo, 01509-900, Brazil
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • Toronto Sunnybrook Hospital
    Toronto, Ontario M4N 3M5, Canada
  • St. Mary's Hospital
    Montreal, Quebec H3T 1M5, Canada
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100021, China
  • Beijing Hospital
    Beijing, Beijing Municipality 100730, China
  • Sun Yat-sen University, Cancer Center
    Guangzhou, Guangdong 510060, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510120, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning 110042, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200032, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin Municipality 300060, China
  • Sir Run Run Shaw Hospital Xiasha Branch, Zhejiang University, School of Medicine
    Hangzhou, Zhejiang 310000, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • Centre Paul Strauss
    Strasbourg, Bas Rhin 67000, France
  • Hôpital Nord - CHU Marseille
    Marseille, Bouches-du-Rhone 13915, France
  • Centre François Baclesse
    Caen, Calvados 14076, France
  • Clinique Victor Hugo - Centre Jean Bernard
    Le Mans, Cedex 02, Sarthe 72015, France
  • CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie
    Plérin, Cotes d'Armor 22190, France
  • Centre Georges François Leclerc
    Dijon, Côte-d'Or 21079, France
  • CHRU Jean Minjoz
    Besançon, Doubs 25030, France
  • Institut Bergonié
    Bordeaux, Gironde 33076, France
  • Centre René Huguenin
    Saint-Cloud, Hauts De Seine 92110, France
  • ICM Val d'Aurelle
    Montpellier, Herault 34298, France
  • CRLCC Eugene Marquis
    Rennes, Ille Et Vilaine 35042, France
  • ICO - Site René Gauducheau
    Saint-Herblain, Loire Atlantique 44805, France
  • ICO - Site Paul Papin
    Angers, Maine Et Loire 49055, France
  • Centre de cancerologie les Dentellieres
    Valenciennes, Nord 59300, France
  • Centre Leon Berard
    Lyon, Rhone 69373, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, Rhone 69495, France
  • Institut Sainte Catherine
    Avignon, Vaculuse 84918, France
  • Hôpital d'Instruction des Armees Begin
    Saint-Mandé, Val De Marne 94160, France
  • Institut Gustave Roussy
    Villejuif, Val De Marne 94805, France
  • Institut Curie - site de Paris
    Paris, 75005, France
  • Hôpital Saint-Louis
    Paris, 75010, France
  • Hopital Tenon
    Paris, 75020, France
  • Universitaetsklinikum Erlangen
    Erlangen, Bavaria 91-54, Germany
  • Rotkreuzklinikum Muenchen gGmbH
    Munich, Bavaria 80637, Germany
  • Klinikum rechts der Isar der TU Muenchen
    Munich, Bavaria 81675, Germany
  • Universitaetsklinikum Duesseldorf AoeR
    Düsseldorf, North Rhine-Westphalia 40225, Germany
  • Haematologisch-Onkologische Schwerpunktpraxis
    Troisdorf, North Rhine-Westphalia 53840, Germany
  • Marienhospital Bottrop gGmbH
    Bottrop, Rhineland-Palatinate 46236, Germany
  • Universitaetsklinikum Schleswig-Holstein - Campus Luebeck
    Lübeck, Schleswig-Holstein 23538, Germany
  • The Chinese
    Hong Kong, 00000, Hong Kong
  • The University of Hong Kong
    Shatin, 00000, Hong Kong
  • Azienda Ospedaliera Universitaria Arcispedale Sant'Anna
    Cona, Ferrara 44124, Italy
  • Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo), U.O Oncologia Medica
    Monza, Milano 20900, Italy
  • Istituto Clinico Humanitas
    Rozzano, Milano 20089, Italy
  • IRCCS Centro di Riferimento Oncologico
    Aviano, Pordenone 33081, Italy
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
    Bergamo, 24127, Italy
  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
    Bologna, 40138, Italy

Showing the first 100 of 164 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Iwata H, Xu B, Kim SB, Chung WP, Park YH, Kim MH, Tseng LM, Chung CF, Huang CS, Kim JH, Chiu JWY, Yamashita T, Li W, Egorov A, Nishijima S, Nakatani S, Nishiyama Y, Sugihara M, Cortes J, Im SA. Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer. Cancer Sci. 2024 Sep;115(9):3079-3088. doi: 10.1111/cas.16234. Epub 2024 Jul 9. PubMed 38979893 ↗
  • Cortes J, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim SB, Chiu JWY, Pedrini JL, Li W, Yonemori K, Bianchini G, Loi S, Borges GS, Wang X, Bachelot T, Nakatani S, Ashfaque S, Liang Z, Egorov A, Hamilton E. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med. 2024 Aug;30(8):2208-2215. doi: 10.1038/s41591-024-03021-7. Epub 2024 Jun 2. PubMed 38825627 ↗
  • Ma R, Shi Y, Yan R, Yin S, Bu H, Huang J. Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2024 Apr;196:104305. doi: 10.1016/j.critrevonc.2024.104305. Epub 2024 Mar 3. PubMed 38442809 ↗
  • Cortes J. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer: a plain language summary of the DESTINY-Breast03 study. Future Oncol. 2024 Feb;20(4):167-178. doi: 10.2217/fon-2023-0422. Epub 2023 Dec 7. PubMed 38059424 ↗
  • Rugo HS, Crossno CL, Gesthalter YB, Kelley K, Moore HB, Rimawi MF, Westbrook KE, Buys SS. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer. JCO Oncol Pract. 2023 Aug;19(8):539-546. doi: 10.1200/OP.22.00480. Epub 2023 May 19. PubMed 37207306 ↗
  • Curigliano G, Dunton K, Rosenlund M, Janek M, Cathcart J, Liu Y, Fasching PA, Iwata H. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study. Ann Oncol. 2023 Jul;34(7):569-577. doi: 10.1016/j.annonc.2023.04.516. Epub 2023 May 12. PubMed 37179020 ↗
  • Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning JW, Curigliano G, Perez-Garcia JM, Kim SB, Petry V, Huang CS, Li W, Frenel JS, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cortes J. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023 Jan 14;401(10371):105-117. doi: 10.1016/S0140-6736(22)02420-5. Epub 2022 Dec 7. PubMed 36495879 ↗
  • Rugo HS, Bianchini G, Cortes J, Henning JW, Untch M. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open. 2022 Aug;7(4):100553. doi: 10.1016/j.esmoop.2022.100553. Epub 2022 Aug 11. PubMed 35964548 ↗
  • Cortes J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. PubMed 35320644 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in May 2021, 33 months.

Results were first posted in Apr 2022, 11 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 33 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Aug 2026, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2018
First posted
May 18, 2018
StartActual
Aug 9, 2018
Primary completionActual
May 21, 2021
CompletionActual
Aug 31, 2026was Jul 2026
Results first posted
Apr 29, 2022
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 7, 2026
Study completion
Jul 30, 2026→Aug 31, 2026 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Active, not recruiting→Completed
    Study completion Jul 30, 2026→Aug 31, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03529110
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
May 18, 2018
Start date
Aug 9, 2018
Primary completion
May 21, 2021
Completion
Aug 31, 2026
Results posted
Apr 29, 2022
Last update
Oct 7, 2026

Study contacts

Global Team Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion